Compare Baker Hughes Co (BKR) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baker Hughes Co vs Moderna, Inc. — how do they compare? Baker Hughes Co trades at $64.5 (market cap $64.34B), while Moderna, Inc. trades at $60.2 (market cap $24.18B). The key difference: Baker Hughes Co is far larger — about 2.7× Moderna, Inc.'s market cap, and Baker Hughes Co pays a 1.42% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| BKR | MRNA | |
|---|---|---|
Market Cap | $64.34B | $24.18B |
Sector | Energy | Health |
52-Week High | $69.67 | $81.80 |
52-Week Low | $42.51 | $22.36 |
Enterprise Value | $64.86B | $20.33B |
Dividend Yield | 1.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Baker Hughes (BKR) trades at $64.07, up 4.09% with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with consistent earnings beats, including Q2 2026 EPS of $0.64 exceeding expectations. Recent contract wins in subsea systems and LNG technology, along with the Chart Industries acquisition, position the company for growth despite modest oil & gas spending headwinds. Operating cash flow reached $3.81 billion in 2025, supporting financial stability.
BKR presents a favorable risk-reward profile with 66.7% analyst buy ratings and a $73.25 consensus target offering 14% upside. Key risks include integration challenges from acquisitions and oil market volatility, but strong backlog and margin expansion support the bullish case. The stock remains attractive for investors seeking energy technology exposure with solid cash flow generation.
Moderna (MRNA) trades at $59.81, up 1.08% today, with a bullish technical signal from moving averages and recent FDA approval for its mRNA flu vaccine mFLUSIVA. Despite beating Q2 2026 EPS estimates, revenue has declined from pandemic peaks, with a net income margin of -142.58% in 2026. The stock faces resistance near $61-$63, while support lies at $56-$59.
Outlook remains mixed; pipeline advancements in flu, Ebola, and oncology offer growth potential, but persistent losses and high valuation ratios pose risks. Analyst consensus is cautious with a $54.33 price target below current levels, reflecting concerns over profitability amid transitioning business focus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Baker Hughes Co
Baker Hughes is a global leader in oilfield services and oilfield equipment, with particularly strong presences in the artificial lift, specialty chemicals, and completions markets. The other half of its business focuses on industrial power generation, process solutions, and industrial asset management, with high exposure to the liquid natural gas market specifically, as well as broader industrials end markets.
Read more on BKR →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
